Heal DJ, Gosden J, Smith SL. A review of late-stage CNS drug candidates for the treatment of obesity. Int J Obes, 2013: 37: 107-117.
Heal DJ, Gosden J, Jackson HC, Cheetham SC, Smith SL. Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity. Handbook Exp Pharmacol, 2012; 212: 135-164.
Lynch CJ, Zhou Q, Shyng SL, Heal DJ, Cheetham SC, Dickinson K, Gregory P, Firnges M, Nordheim U, Goshorn S, Reiche D, Turski L, Antel J. Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels. Am J Physiol Endocrinol Metab. 2012; 302: E540-51.
Heal DJ, Gosden J, Smith SL. What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacol, 2012; 63: 132-146.
Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol, 2009; 68: 861-874.
Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther. 2008; 117: 207-231.
Heal DJ. Obesity drug development - CBI's 2nd Annual Summit. Drugs, 2006; 9: 682-5.
Woolard J, Bennett T, Dunn WR, Heal DJ, Aspley S, Gardiner SM. Acute cardiovascular effects of sibutramine in conscious rats. J Pharmacol Exp Ther, 2004; 308: 1102-10.
Cheetham SC, Jackson HC, Vickers SP, Dickinson K, Jones RB, and Heal DJ. Novel targets for the treatment of obesity: a review of progress. Drug Disc Today, 2004; 1: 227-235.
Heal DJ, Rowley HL and Jackson HC. Delivering the next generation of anti-obesity therapies – challenges for pharmacogenomics, patients and the pharmaceutical industry. In: Progress in Obesity Research, Volume 9. Eds: Medeiros-Nero G, Halpern A and Bouchard C. pp 260-264. John Libbey, Paris, 2003.
Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord. 1998; 22 (Suppl 1): S18-28; discussion S29.